spacer
home > ict > summer 2019 > therapeutic oncology and the road ahead
PUBLICATIONS
International Clinical Trials

Therapeutic Oncology and the Road Ahead




ICT: What trends are you seeing in therapeutic oncology?

Dr Tim Williams: We are seeing significant interest in the application of remote, digital patient-reported outcomes measurement (PROMs) to enhance routine cancer care in the UK. There is growing awareness of the importance in quality of life as more people live with and beyond cancer, as well as a drive for new approaches to support cancer service delivery and better care for patients over the long term, focusing on acute treatment at a time when the workforce faces increased pressure.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Dr Tim Williams is the Co-Founder and CEO of My Clinical Outcomes (MCO), a clinical technology platform that automates the collection and analysis of PROMs in routine clinical practice. Tim previously worked as an NHS doctor and Strategy Consultant and has a keen interest in how technology can help improve healthcare services. MCO is in use at over 70 UK public and private hospitals in a range of conditions and specialties and is now working on several innovative projects helping to support the care of cancer patients in the NHS.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement